Digiesi, V.; Nassi, P.; Cicchi, P.; Castigli, E.; Ramponi, G.; Arcangeli, P.
July 1975
Angiology;Jul/Aug1975, Vol. 26 Issue 7, p511
Academic Journal
Some enzymatic activities have been essayed in the gastrocnemius muscle of patients with obstructive arteriopathy of the lower limbs. The specific activities of all the examined glycolytic enzymes, of malate dehydrogenase and of glycerol-3-phosphate dehydrogenase are significantly decreased while the specific activities of two lysosomal enzymes, β-glucuronidase and cathepsin A, are significantly higher than in the controls. Therefore it may be inferred that the metabolic capacity of glycolysis and of Krebs cycle are lowered. On the other hand the increased specific activity of lysosomal enzymes suggests the hypothesis that the above mentioned modifications and the morphologic alterations of the muscle and of the small blood vessels might be ascribed, at least partly, to a release of lysosomal hydrolases in active form.


Related Articles

  • Molecular Pathologies of and Enzyme Replacement Therapies for Lysosomal Diseases. Sakuraba, Hitoshi; Sawada, Makoto; Matsuzawa, Fumiko; Aikawa, Sei-ichi; Chiba, Yasunori; Jigami, Yoshifumi; Itoh, Kohji // CNS & Neurological Disorders - Drug Targets;2006, Vol. 5 Issue 4, p401 

    Lysosomal diseases comprise a group of inherited disorders resulting from defects of lysosomal enzymes and their cofactors, and in many of them the nervous system is affected. Recently, enzyme replacement therapy with recombinant lysosomal enzymes has been clinically available for several...

  • Home Therapy for Lysosomal Storage Diseases. Hughes, Derralyn A.; Milligan, Alan; Mehta, Atul B. // Current Medical Literature: Lysosomal Storage Disease;2007, Vol. 7 Issue 1, p1 

    The article focuses on the impact of intravenous enzyme replacement therapy (ERT) on patients with lysosomal storage diseases (LSDs). The therapy transforms the duration of the patients treatment. The delivery of the ERT in the home environment will result to cost saving due to its effectiveness...

  • New mutations in the GLA gene in Brazilian families with Fabry disease. Turaça, Lauro Thiago; Pessoa, Juliana Gilbert; Motta, Fabiana Louise; Muñoz Rojas, Maria Verônica; Müller, Karen Barbosa; Lourenço, Charles Marques; Junior Marques, Wilson; D'Almeida, Vania; Martins, Ana Maria; Pesquero, João Bosco // Journal of Human Genetics;Jun2012, Vol. 57 Issue 6, p347 

    Fabry disease (FD) is an X-linked inborn error of glycosphingolipid catabolism that results from mutations in the alpha-galactosidase A (GLA) gene. Evaluating the enzymatic activity in male individuals usually performs the diagnosis of the disease, but in female carriers the diagnosis based only...

  • Protective Effects of Positive Lysosomal Modulation in Alzheimer's Disease Transgenic Mouse Models. Butler, David; Jeannie Hwang; Estick, Candice; Nishiyama, Akiko; Santhosh Kumar, Saranya; Baveghems, Clive; Young-Oxendine, Hollie B.; Wisniewski, Meagan L.; Charalambides, Ana; Bahr, Ben A. // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    Alzheimer's disease (AD) is an age-related neurodegenerative pathology in which defects in proteolytic clearance of amyloid &bgr;peptide (A&bgr;) likely contribute to the progressive nature of the disorder. Lysosomal proteases of the cathepsin family exhibit up-regulation in response to...

  • lysosomal storage disease.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1383 

    A definition of the term "lysosomal storage disease" which refers to a disease caused by deficiency of specific lysosomal enzymes that normally degrade glycoproteins, glycolipids, or mucopolysaccharides is presented.

  • Correction: Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Desnick, Robert J.; Schuchman, Edward H. // Nature Reviews Genetics;Feb2003, Vol. 4 Issue 2, p157 

    Presents correction to the study 'Enzyme Replacement and Enhancement Therapies: Lessons From Lysosomal Disorders,' by Robert J. Desnick and Edward H. Schuchman, published in the 2002 issue of the 'Nature Reviews Genetics' journal.

  • Accelerated transport and maturation of lysosomal α?galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Fan, Jian-Qiang; Ishii, Satoshi; Asano, Naoki; Suzuki, Yoshiyuki // Nature Medicine;Jan1999, Vol. 5 Issue 1, p112 

    Fabry disease is a disorder of glycosphingolipid metabolism caused by deficiency of lysosomal α-galactosidase A (α-Gal A), resulting in renal failure along with premature myocardial infarction and strokes. No effective treatment of this disorder is available at present. Studies of residual...

  • Human α-N-acetylgalactosaminidase (α-NAGA) deficiency: no association with neuroaxonal dystrophy? Bakker, Henk D; de Sonnaville, Marie-Louise CS; Vreken, Peter; Abeling, Nico GGM; Groener, Johanna EM; Keulemans, Joke LM; van Diggelen, Otto P // European Journal of Human Genetics;Feb2001, Vol. 9 Issue 2, p91 

    Two new individuals with α-NAGA deficiency are presented. The index patient, 3 years old, has congenital cataract, slight motor retardation and secondary demyelinisation. Screening of his sibs revealed an α-NAGA deficiency in his 7-year-old healthy brother who had no clinical or...

  • Enzyme Replacement Therapy for Lysosomal Storage Disorders. Sayut, Daniel J.; Kambam, Pavan K. R.; Sun, Lianhong // Recent Patents on Biomedical Engineering;Jun2008, Vol. 1 Issue 2, p141 

    Abstract: Enzyme replacement therapy is the only authorized method for treating lysosomal storage disorders. During the last ten years, this method has been demonstrated to be both safe and effective for the treatment of many lysosomal storage disorder patients. Recent advances in enzyme...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics